To evaluate the immunization of HBV vaccine with double dose comparing standard dose in chronic liver disease patients in Isfahan city 2010-2011

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT138902153873N1

Enrollment

Registered

2010-10-29

Start date

2010-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic viral hepatitis C. Chronic viral hepatitis C

Interventions

HBV vaccine (Hepavax-Gene), in months 0, 1, and 6, intramuscular injection

HBV vaccine (Hepavax-Gene), in months 0, 1, and 6, intramuscular injection.

Prevention

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Age 18-65 years old, documented chronic HCV positive or cirrhosis Exclusion criteria: previously HBV vaccination or HBV positive, alcoholic cirrhosis or hepatitis, immune deficiency, CKD with GFR<60ml/min/1.73m2 5, autoimmune hepatitis or cirrhosis

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Anti HBS titer. Timepoint: Before & 1 month after intervention. Method of measurement: ELISA reader.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Mohammad Minakari

Isfahan University of Medical Sciences

mminakari@yahoo.com+98 31 1625 5555

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026